KR102656524B1 - 연골형성을 유도하기 위한 화합물 및 조성물 - Google Patents

연골형성을 유도하기 위한 화합물 및 조성물 Download PDF

Info

Publication number
KR102656524B1
KR102656524B1 KR1020207000290A KR20207000290A KR102656524B1 KR 102656524 B1 KR102656524 B1 KR 102656524B1 KR 1020207000290 A KR1020207000290 A KR 1020207000290A KR 20207000290 A KR20207000290 A KR 20207000290A KR 102656524 B1 KR102656524 B1 KR 102656524B1
Authority
KR
South Korea
Prior art keywords
compound
substituted
carboxamide
oxabicyclo
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207000290A
Other languages
English (en)
Korean (ko)
Other versions
KR20200013046A (ko
Inventor
하-순 최
지칭 장
제임스 폴 라지네스
바오 응우엔
행크 마이클 제임스 페트라시
즈청 왕
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20200013046A publication Critical patent/KR20200013046A/ko
Application granted granted Critical
Publication of KR102656524B1 publication Critical patent/KR102656524B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0655—Chondrocytes; Cartilage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/14—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from hepatocytes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020207000290A 2017-06-09 2018-06-07 연골형성을 유도하기 위한 화합물 및 조성물 Active KR102656524B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762517394P 2017-06-09 2017-06-09
US62/517,394 2017-06-09
PCT/IB2018/054123 WO2018225009A1 (en) 2017-06-09 2018-06-07 Compounds and compositions for inducing chondrogenesis

Publications (2)

Publication Number Publication Date
KR20200013046A KR20200013046A (ko) 2020-02-05
KR102656524B1 true KR102656524B1 (ko) 2024-04-12

Family

ID=62837959

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207000290A Active KR102656524B1 (ko) 2017-06-09 2018-06-07 연골형성을 유도하기 위한 화합물 및 조성물

Country Status (37)

Country Link
US (3) US11091499B2 (cg-RX-API-DMAC7.html)
EP (3) EP3634967A1 (cg-RX-API-DMAC7.html)
JP (2) JP7229945B2 (cg-RX-API-DMAC7.html)
KR (1) KR102656524B1 (cg-RX-API-DMAC7.html)
CN (1) CN110719913B (cg-RX-API-DMAC7.html)
AR (1) AR113227A1 (cg-RX-API-DMAC7.html)
AU (1) AU2018279306C1 (cg-RX-API-DMAC7.html)
BR (1) BR112019025866A2 (cg-RX-API-DMAC7.html)
CL (1) CL2019003564A1 (cg-RX-API-DMAC7.html)
CO (1) CO2019013706A2 (cg-RX-API-DMAC7.html)
CR (1) CR20190551A (cg-RX-API-DMAC7.html)
CU (1) CU24577B1 (cg-RX-API-DMAC7.html)
DK (1) DK3915994T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2019000305A (cg-RX-API-DMAC7.html)
EA (1) EA201992858A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP19086712A (cg-RX-API-DMAC7.html)
ES (1) ES2971319T3 (cg-RX-API-DMAC7.html)
FI (1) FI3915994T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20240155T1 (cg-RX-API-DMAC7.html)
HU (1) HUE065194T2 (cg-RX-API-DMAC7.html)
IL (2) IL300755A (cg-RX-API-DMAC7.html)
JO (1) JOP20190282B1 (cg-RX-API-DMAC7.html)
LT (1) LT3915994T (cg-RX-API-DMAC7.html)
MA (2) MA50547A (cg-RX-API-DMAC7.html)
MX (1) MX389169B (cg-RX-API-DMAC7.html)
MY (1) MY198288A (cg-RX-API-DMAC7.html)
PE (1) PE20200403A1 (cg-RX-API-DMAC7.html)
PH (1) PH12019502764A1 (cg-RX-API-DMAC7.html)
PL (1) PL3915994T3 (cg-RX-API-DMAC7.html)
PT (1) PT3915994T (cg-RX-API-DMAC7.html)
RS (1) RS65161B1 (cg-RX-API-DMAC7.html)
SA (1) SA519410729B1 (cg-RX-API-DMAC7.html)
SI (1) SI3915994T1 (cg-RX-API-DMAC7.html)
TW (1) TWI782036B (cg-RX-API-DMAC7.html)
UY (1) UY37759A (cg-RX-API-DMAC7.html)
WO (1) WO2018225009A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201907358B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY37759A (es) * 2017-06-09 2019-01-31 Novartis Ag Compuestos y composiciones para inducir condrogénesis
ES2963508T3 (es) * 2018-12-06 2024-03-27 Novartis Ag Derivados de 5-hidroxi-7-oxabiciclo[2.2.1]heptano-2-carboxamida para inducir condrogénesis para el tratamiento del daño articular
WO2020115684A1 (en) * 2018-12-06 2020-06-11 Novartis Ag 6-hydroxy-8-oxatricyclo[3.2.1.02,4]octane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077864A (en) 1997-01-06 2000-06-20 Pfizer Inc. Cyclic sulfone derivatives
ECSP982358A (es) 1998-01-06 1998-12-22 Derivados ciclicos de sulfona
US6407250B1 (en) * 2000-09-14 2002-06-18 Allergan Sales, Inc. Interphenylene 7-oxabicyclic [2.2.1] heptane oxazoles as prostaglandin F2a antagonists
US6369089B1 (en) 2000-09-14 2002-04-09 Allergan Sales, Inc. Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists
CN1213050C (zh) 2000-11-23 2005-08-03 拜尔公司 氧杂双环[2.2.1]庚烷衍生物,其制备方法和作为农药的用途
US6653468B1 (en) 2002-07-31 2003-11-25 Isis Pharmaceuticals, Inc. Universal support media for synthesis of oligomeric compounds
JP2005068052A (ja) 2003-08-22 2005-03-17 Mitsui Chemicals Inc 新規なフラン誘導体及びその製造方法
WO2006038112A1 (en) 2004-10-01 2006-04-13 Warner-Lambert Company Llc Use of kinase inhibitors to promote neochondrogenesis
US7595327B2 (en) * 2005-03-21 2009-09-29 Wyeth Beta-sulfonamide hydroxamic acid inhibitors of tace/matrix metalloproteinase
US9233106B2 (en) 2006-07-12 2016-01-12 Cornell Research Foundation, Inc. Inhibition of beta-amyloid peptide aggregation
JO3240B1 (ar) 2007-10-17 2018-03-08 Janssen Pharmaceutica Nv c-fms مثبطات كيناز
WO2010114997A1 (en) 2009-04-02 2010-10-07 Allergan, Inc. Prostaglandin e receptor antagonists
PE20160507A1 (es) 2009-07-14 2016-05-20 Scripps Research Inst Diferenciacion de celulas madre mesenquimales
CN101628951B (zh) 2009-08-12 2011-06-22 中国石油天然气股份有限公司 烯烃聚合用固体催化组分及其催化剂
EP2651405A2 (en) 2010-12-14 2013-10-23 Electrophoretics Limited Casein kinase 1 (ck1 ) inhibitors
WO2012129562A2 (en) 2011-03-24 2012-09-27 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
WO2012177856A2 (en) 2011-06-21 2012-12-27 Adispell, Inc. Cognition modification
WO2013007765A1 (en) * 2011-07-13 2013-01-17 F. Hoffmann-La Roche Ag Fused tricyclic compounds for use as inhibitors of janus kinases
EP2968330B1 (en) * 2013-03-15 2021-09-29 The Scripps Research Institute Compounds and methods for inducing chondrogenesis
HRP20241236T1 (hr) * 2014-05-13 2024-12-06 Novartis Ag Spojevi i pripravci za induciranje hondrogeneze
JP2016204316A (ja) 2015-04-24 2016-12-08 日東電工株式会社 核酸固相合成用リンカー及び担体
UY37759A (es) 2017-06-09 2019-01-31 Novartis Ag Compuestos y composiciones para inducir condrogénesis

Also Published As

Publication number Publication date
EP4299123A2 (en) 2024-01-03
EP4299123A3 (en) 2024-04-03
TW201902900A (zh) 2019-01-16
MX389169B (es) 2025-03-20
JOP20190282B1 (ar) 2024-04-18
IL300755A (en) 2023-04-01
CN110719913A (zh) 2020-01-21
JP7432778B2 (ja) 2024-02-16
NZ759434A (en) 2024-01-26
CO2019013706A2 (es) 2020-04-01
RU2019144107A3 (cg-RX-API-DMAC7.html) 2021-07-30
PH12019502764A1 (en) 2020-07-13
AU2018279306A1 (en) 2019-12-05
US20210079010A1 (en) 2021-03-18
HRP20240155T1 (hr) 2024-04-12
CN110719913B (zh) 2022-10-28
PE20200403A1 (es) 2020-02-26
CU24577B1 (es) 2022-02-04
EP3634967A1 (en) 2020-04-15
MA50547A (fr) 2020-09-16
BR112019025866A2 (pt) 2020-07-14
CR20190551A (es) 2020-01-28
FI3915994T3 (fi) 2024-02-14
MA57022B1 (fr) 2024-02-29
IL271154B2 (en) 2023-07-01
JP2023062064A (ja) 2023-05-02
SA519410729B1 (ar) 2022-07-03
PT3915994T (pt) 2024-02-15
JP7229945B2 (ja) 2023-02-28
JOP20190282A1 (ar) 2019-12-05
DOP2019000305A (es) 2019-01-15
TWI782036B (zh) 2022-11-01
ES2971319T3 (es) 2024-06-04
US20230365580A1 (en) 2023-11-16
IL271154B1 (en) 2023-03-01
WO2018225009A1 (en) 2018-12-13
PL3915994T3 (pl) 2024-05-20
EP3915994A1 (en) 2021-12-01
KR20200013046A (ko) 2020-02-05
US20210347784A1 (en) 2021-11-11
CU20190098A7 (es) 2020-10-20
US12209096B2 (en) 2025-01-28
EP3915994B9 (en) 2024-02-28
AU2018279306C1 (en) 2021-01-14
MX2019014757A (es) 2020-02-12
AU2018279306B2 (en) 2020-07-09
AR113227A1 (es) 2020-02-19
DK3915994T3 (da) 2024-02-19
MY198288A (en) 2023-08-21
CL2019003564A1 (es) 2020-06-19
ZA201907358B (en) 2022-04-28
US11753416B2 (en) 2023-09-12
UY37759A (es) 2019-01-31
IL271154A (en) 2020-01-30
EA201992858A1 (ru) 2020-04-02
EP3915994B1 (en) 2023-11-22
CA3063985A1 (en) 2018-12-13
RU2019144107A (ru) 2021-07-09
RS65161B1 (sr) 2024-02-29
JP2020522550A (ja) 2020-07-30
HUE065194T2 (hu) 2024-05-28
SI3915994T1 (sl) 2024-03-29
LT3915994T (lt) 2024-02-26
US11091499B2 (en) 2021-08-17
ECSP19086712A (es) 2019-12-27

Similar Documents

Publication Publication Date Title
EP3143026B1 (en) Compounds and compositions for inducing chondrogenesis
JP7432778B2 (ja) 軟骨形成を誘導するための化合物及び組成物
EP3891154B1 (en) 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
RU2773943C2 (ru) Соединения и композиции для индуцирования хондрогенеза
HK40096806A (en) Compounds and compositions for inducing chondrogenesis
HK40055222A (en) Compounds and compositions for inducing chondrogenesis
HK40055222B (en) Compounds and compositions for inducing chondrogenesis
EA040531B1 (ru) Соединения и композиции для индукцирования хондрогенеза
HK40112804A (en) Compounds and compositions for inducing chondrogenesis
HK1231467B (en) Compounds and compositions for inducing chondrogenesis

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601